Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/7219| Title: | Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial | Authors: | Delaloge, S Cella, D Ye, Y Buyse, M Chan, A Barrios, C H Holmes, F A Mansi, J Iwata, H Ejlertsen, B Moy, B Chia, S K L Gnant, M Smichkoska, Snezhana Ciceniene, A Martinez, N Filipović, S Ben-Baruch, N E Joy, A A Langkjer, S T Senecal, F de Boer, R H Moran, S Yao, B Bryce, R Auerbach, A Fallowfield, L Martin, M |
Keywords: | early-stage breast cancer | Issue Date: | 2019 | Publisher: | Elsevier BV | Journal: | Annals of Oncology | Abstract: | We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer. | URI: | http://hdl.handle.net/20.500.12188/7219 | DOI: | 10.1093/annonc/mdz016 |
| Appears in Collections: | Faculty of Medicine: Journal Articles |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.